GlassScriptPhysician profile
Shicong Ye
NPI 1912918194
$3,538.46
in general payments reported to CMS, 2019-2025
15 companies · $883 in 2025
The $883 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,247 · 2021: $30.15 · 2022: $71.96 · 2024: $1,307 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Travel and Lodging: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.54 |
| Travel and Lodging | $461.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,071.32 | 2019-2024 | Vns Therapy |
| Abbvie INC. | $320.15 | 2025 | |
| Ucb, INC. | $251.91 | 2022-2025 | Fintepla, Briviact |
| Supernus Pharmaceuticals, INC. | $242.44 | 2024-2025 | Qelbree |
| Eisai INC. | $143.72 | 2019-2025 | |
| Greenwich Biosciences, INC. | $131.95 | 2019 | |
| Amgen INC. | $120.29 | 2019 | |
| Axsome Therapeutics, INC. | $113.07 | 2025 | Symbravo |
| Sk Life Science, INC. | $59.37 | 2025 | |
| Merz Pharmaceuticals, LLC | $30.95 | 2025 | Xeomin, Inbrija, Ampyra |
| Amneal Pharmaceuticals LLC | $21.01 | 2025 | Crexont |
| Alexion Pharmaceuticals, INC. | $20.09 | 2025 | Ultomiris |
| Allergan, INC. | $12.19 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shicong Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.